Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pharmatek Announces Acquisition of Additional Xcelodose® 600S System

Published: Thursday, February 07, 2013
Last Updated: Wednesday, February 06, 2013
Bookmark and Share
Acquisition enables increased capacity to meet growing demand for powder in a capsule.

Pharmatek has announced that it has purchased another Xcelodose® 600S system.

This acquisition doubles the company's manufacturing production rate for powder-in-capsule (PIC) operations and increases overall preclinical and early phase clinical cGMP supply capabilities.

"The acquisition of an additional Xcelodose® unit enables Pharmatek to better serve our clients' early phase development strategies and meet the growing demand for PIC projects," stated Kevin Rosenthal, Director of Manufacturing at Pharmatek.

Rosenthal continued, "For PIC applications, the Xcelodose® can drastically decrease time to clinic while also lowering the cost of drug product for first-in-human trials."

In addition to adding another Xcelodose® system, Pharmatek has implemented a dedicated Xcelodose® project team to ensure the overall success and quick turnaround of PIC programs.

Each team is led by an Xcelodose® engineer who oversees the project from planning to execution.

The Xcelodose®, manufactured by Capsugel, is a precision powder micro-doser and automated encapsulator that has the ability to fill formulations or active pharmaceutical ingredient (API) directly into capsules with a remarkable level of accuracy.

The Xcelodose® can measure to levels as low as 100 micrograms and can dispense into capsules from size 00 to 4. Dosing directly into capsules can reduce the amount of API required.

Additionally, the unit minimizes overall development time by simplifying analytical and stability protocols.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pharmatek Expands Spray Drying Capabilities
New spray dryer strengthens the Company’s portfolio of solutions for poorly soluble compounds.
Friday, May 22, 2015
Pharmatek Expands Packaging Services
Installation and qualification of an automated bottling line at San Diego facility.
Thursday, October 17, 2013
CMO Laboratory Expands GMP Manufacturing Capabilities
Pharmatek Laboratories, Inc. have announced that it has added roller compaction to its solid oral dosage form manufacturing capabilities. The company has purchased two roller compactors, a pilot-scale. Both machines have been integrated into Pharmatek’s GMP facility and are ready for GMP manufacturing.
Thursday, November 25, 2010
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!